UBS Group
TAK icon

UBS Group’s Takeda Pharmaceutical TAK Stock Holding History

UBS Group’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-68,700
Closed -$936K – 10878
2021
Q4 		$936K Sell
68,700
-1,000
-1% -$14K ﹤0.01% 4449
2021
Q3 		$1.14M Buy
69,700
+1,000
+1% +$16.8K ﹤0.01% 4078
2021
Q2 		$1.16M Hold
68,700
– – ﹤0.01% 4057
2021
Q1 		$1.25M Buy
+68,700
New +$1.24M ﹤0.01% 4025

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

UBS Group's TAK Position: Q1 2026 in Review

UBS Group reduced its Takeda Pharmaceutical (TAK) stake by 34% in Q1 2026, selling an estimated $24.3M and leaving 2,740,229 shares worth $50.7M. The position accounts for 0.01% of the portfolio, ranked #1621.

UBS Group first reported a position in TAK in Q4 2018 and has held it in 30 quarters since. The position peaked at $171M in Q4 2018. 359 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

  • UBS Group held 2,740,229 shares of Takeda Pharmaceutical worth $50.7M as of Q1 2026.
  • UBS Group sold 1,383,294 Takeda Pharmaceutical shares in Q1 2026, an estimated $24.3M.
  • Takeda Pharmaceutical made up 0.01% of UBS Group's portfolio in Q1 2026, its #1621 holding.
  • UBS Group first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 30 quarters since.
  • UBS Group's Takeda Pharmaceutical position peaked at $171M in Q4 2018.
  • 359 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.